Wegovy Savings Card: Eligibility and Limits

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide vs Ozempic and Wegovy comparison hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last March, a woman named Rachel in suburban Denver called her pharmacy to fill her third month of Wegovy. She had the savings card loaded into her account. The first two fills had come through at $25 each. This time, the pharmacist told her the copay was $1,349. Her insurer had quietly moved Wegovy to a non-preferred tier during a mid-year formulary revision, and the savings card couldn't bridge the gap. "I thought the card was the safety net," she told her prescriber's office. "Nobody explained that the card only works if insurance already says yes."

Rachel's confusion is extremely common, and it's the reason "wegovy savings card" deserves a more honest treatment than most patients get.

This article is part of the broader Compounded Semaglutide vs Ozempic and Wegovy cluster, which feeds into the compounded semaglutide pillar guide.

What the Wegovy Savings Card Actually Does (and Doesn't)

The Wegovy savings card is a manufacturer copay assistance program from Novo Nordisk. It reduces the out-of-pocket cost per fill for patients who meet specific criteria. The structure: a maximum copay reduction per fill, capped at a maximum dollar amount per calendar year.

Here's the thing most patients miss. The card is a copay reducer, not a coverage tool. It shaves dollars off a copay that already exists under your commercial insurance plan. If your plan doesn't cover Wegovy at all, or if your plan requires a prior authorization you haven't obtained, the card does exactly nothing.

Eligibility requirements:

You must have commercial (private) insurance.
Your prescription must be written by a licensed clinician for an on-label indication.
You cannot be enrolled in Medicare, Medicaid, TRICARE, the VA, or any other federal or state government-funded healthcare program.

That last exclusion knocks out a significant chunk of the patient population seeking GLP-1 therapy for weight management, particularly adults over 65.

Where the Card Falls Apart

The most predictable failure mode is formulary changes. Insurance plans revise their formularies regularly, sometimes mid-year. A drug that was Tier 2 in January can land on Tier 4 in July, or get excluded entirely. The savings card can't override a formulary exclusion. It can't substitute for a denied prior authorization. It can't turn a non-covered drug into a covered one.

If your plan drops Wegovy from its formulary, your options are: file a formulary exception appeal (slow, uncertain), switch to a different covered GLP-1 medication, or pay cash. Cash price for Wegovy in 2026 hovers around $1,300 to $1,400 per month depending on dose and pharmacy. For most people, that's not sustainable long-term.

The savings card also has annual caps. Once you've hit that ceiling, you're back to paying whatever your plan's copay or coinsurance actually is. Patients who start therapy mid-year and assume the card will last through December sometimes run into an unpleasant surprise around month eight or nine.

The Branded vs. Compounded Question Underneath All of This

Every conversation about Wegovy savings cards eventually becomes a conversation about cost, which eventually becomes a conversation about compounded semaglutide. The two pathways use the same active molecule but differ in almost every other dimension.

Wegovy and Ozempic are FDA-approved branded products manufactured by Novo Nordisk. Wegovy is labeled for chronic weight management; Ozempic is labeled for type 2 diabetes. Same molecule, different dose ceilings, different indications.

Compounded semaglutide is prepared by a licensed compounding pharmacy under a patient-specific clinician prescription. It uses semaglutide as the active ingredient. It is not FDA-approved. It has not been independently tested in randomized trials at the same scale as the branded products. The clinical evidence base for semaglutide as a molecule comes from the branded trial programs.

The boring truth: neither "compounded is just as good" nor "compounded is dangerous" captures reality. The active ingredient is the same. The regulatory pathway, manufacturing oversight, and supply chain are different. That difference matters, and it's a conversation for you and your prescriber, not something a savings card resolves.

What the Trial Data Actually Shows

The dosing and efficacy numbers that inform every clinical decision about semaglutide come from a handful of major trial programs:

STEP-1 tested 2.4 mg weekly semaglutide against placebo over 68 weeks. The active arm reported a mean 14.9 percent weight loss from baseline. That's a population average. Individual responses ranged widely.

STEP-3 added a structured lifestyle intervention (intensive behavioral therapy, meal replacements for part of the trial) to the same protocol and reported higher mean weight loss. The reading: lifestyle effort is additive. The medication doesn't do the work alone.

STEP-4 is the one that should concern every patient thinking about long-term planning. Participants who switched from active semaglutide to placebo at week 20 showed partial weight regain over the subsequent 48 weeks. The chronic biology of weight regulation reasserts itself when you stop the drug, the same way blood pressure climbs back up when you stop an antihypertensive. This is not a course of antibiotics.

SUSTAIN-6 and LEADER anchor the cardiovascular safety profile for the GLP-1 class. SELECT, completed in 2023, reported a 20 percent relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity without diabetes. That's a meaningful signal, and it's one reason insurance coverage for these drugs is slowly (very slowly) expanding.

None of these trials were conducted with compounded preparations. The molecular evidence applies across forms. The manufacturing and regulatory confidence does not.

Misconceptions That Keep Showing Up

"If I have worse nausea, the drug is working better." Trial data from STEP-1 and STEP-3 don't support this. Patients with mild GI side effects and patients with significant nausea both achieved meaningful weight loss. Side effect intensity is not a proxy for efficacy.

"The savings card makes Wegovy affordable." It makes the copay more manageable for commercially insured patients whose plans already cover Wegovy. That's a narrower group than the marketing implies.

"Compounded semaglutide is the same thing, just cheaper." The active ingredient is the same. The regulatory status is not. Compounding pharmacies operate under a different framework (503A or 503B), with different manufacturing oversight, and compounded preparations are not FDA-approved. Price is lower. The tradeoffs are real and worth discussing with your clinician.

"I can stop once I hit my goal weight." STEP-4 says otherwise. Weight-regulating biology is persistent. Most obesity medicine physicians frame semaglutide as chronic therapy, not a temporary fix.

So What Should You Actually Do?

If you're evaluating a Wegovy savings card, check three things before you fill:

Confirm your plan covers Wegovy on its current formulary. Call the number on the back of your insurance card. Don't rely on what was true six months ago.
Complete prior authorization before assuming the card will work. Many plans require PA for GLP-1 medications. The savings card activates after coverage is confirmed, not before.
Calculate your annual cap. If you're starting in October, you may have only a few months of card benefit before the annual reset. Plan accordingly.

If the card path doesn't work, the alternatives are formulary appeals, switching to a covered GLP-1 alternative, cash-pay branded at full price, or compounded semaglutide through a licensed prescriber and compounding pharmacy. Each carries its own cost, regulatory, and clinical profile. The clinician relationship, meaning someone who adjusts dosing based on your response, manages side effects, and follows up between refills, matters more than which pathway you choose.

This article sits within the Compounded Semaglutide vs Ozempic and Wegovy cluster. For a full treatment of the molecule, the 503A and 503B compounding framework, and the broader clinical evidence, the compounded semaglutide pillar guide is the primary reference on this site.

Adjacent Reading

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic or Wegovy?

Compounded semaglutide uses the same active ingredient, semaglutide. It is prepared by a licensed compounding pharmacy under a clinician prescription and is not FDA-approved. Wegovy and Ozempic are FDA-approved branded products manufactured by Novo Nordisk.

What evidence applies across these forms?

The clinical trial evidence for semaglutide as a molecule comes from the SUSTAIN, STEP, and SELECT programs, conducted with the branded products. Compounded preparations have not undergone equivalent trials.

Can patients switch between forms?

Switching between compounded and branded semaglutide is a clinical decision that depends on dose, tolerability, and access. It requires prescriber supervision and is not something to do on your own.

Does the Wegovy savings card work if my insurance doesn't cover Wegovy?

No. The card reduces copays on covered prescriptions. If your plan excludes Wegovy or denies prior authorization, the card cannot bridge that gap.

Who is ineligible for the Wegovy savings card?

Patients on Medicare, Medicaid, TRICARE, the VA, or other federal or state government healthcare programs are excluded. You must have commercial insurance and an on-label prescription.

What happens when the savings card's annual cap runs out?

You pay whatever copay or coinsurance your insurance plan specifies without the manufacturer discount. For many patients, this means a significant cost increase mid-year.

Is the savings card a reason to choose Wegovy over compounded semaglutide?

It's a financial consideration, not a clinical one. The card can reduce short-term out-of-pocket costs for eligible patients, but it doesn't change the clinical evaluation of which form of semaglutide is appropriate for your situation.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.